Polaryx Therapeutics (PLYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Jul, 2026Executive summary
Annual meeting scheduled for September 10, 2026, at 9:00 a.m. Eastern Time, to be held virtually.
Shareholders are encouraged to review proxy materials online and may request paper or email copies at no charge.
Voting matters and shareholder proposals
Election of Class I Directors with nominees Alex Yang, J.D., LL.M, and Mitchel Berger, M.D.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting "FOR ALL NOMINEES" and "FOR" the auditor ratification proposal.
Board of directors and corporate governance
Board is presenting two nominees for election as Class I Directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Polaryx Therapeutics
- PLX-200 advances in a flexible Phase 2 trial, targeting multiple LSDs with strong preclinical support.PLYX
Corporate presentation - Net loss narrowed, cash boosted by equity raise, and runway extends through Q1 2027.PLYXQ2 2026
- PLX-200 targets multiple rare pediatric LSDs with strong preclinical data and a flexible Phase 2 trial.PLYXCorporate presentation
- Shareholders will vote on director elections and auditor ratification, with strong governance and oversight.PLYXProxy filing
- PLX-200 targets multiple rare pediatric LSDs with strong preclinical data and flexible clinical strategy.PLYXCorporate presentation
- Q1 2026 net loss fell to $2.5M; cash runway extends through Q3 2026, further funding required.PLYXQ1 2026
- Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026.PLYXQ4 2025
- PLX-200 advances in a flexible Phase 2 trial for rare pediatric LSDs, targeting broad market impact.PLYXCorporate presentation
- Pre-revenue biotech with a lead LSD therapy pursues Nasdaq direct listing, faces funding needs.PLYXRegistration Filing